NCT03087760已完成2 期
Phase II Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Number of Subjects With Progression Free Survival
研究概览
简要总结
The main purpose of this study is to assess the safety, tolerability and anti-tumor activity of the experimental study drug pembrolizumab (also known as Keytruda or MK-3475) in people with non-small cell lung cancer (NSCLC) that has come back after radiation therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or cytologic diagnosis of NSCLC who have received previous intrathoracic radiation therapy with definitive intent and have a tumor recurrence in or near the prior irradiation fields. Re-biopsy of the recurrence is not required and is left to the discretion of the treating physician, although every effort should be made to confirm recurrence pathologically.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Age 18 or greater
- •Patients with prior invasive malignancies are allowed, provided they have been treated with definitive intent and have no evidence of active disease requiring treatment in the past 2 years.
- •Patients must be capable of giving informed consent and be willing and able to comply with schedule.
- •Serum total bilirubin ≤ 1.5 X upper limit of normal (ULN) OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN.
- •Platelets >100,000 cells/mm3 and ANC > 1,250 cells/mm3
- •Creatinine ≤ 1.5 X ULN OR measured or calculated creatinine clearance ≥50 mL/min for subject with creatinine levels > 1.5 X institutional ULN. (GFR can also be used in place of creatinine or CrCl).
- •Clinical target volume (CTV) size must be <250 cc, no more than 74 Gy of prior radiation in 2 Gy fractions previously administered.
排除标准
- •Allergy to Pembrolizumab or related compounds
- •History of symptomatic CTCAEv4 grade ≥3 pneumonitis following the initial course of definitive radiation therapy
- •History of symptomatic idiopathic pulmonary fibrosis or interstitial lung disease
- •Use of continuous oxygen
- •Diagnosis of immunodeficiency or exposure to systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. (Nasal or oral inhalers are permissible).
- •Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy are an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections are not excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome are not excluded from the study.
- •History of allogenic tissue or solid organ transplant
- •Progression while on prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
- •Patients with known extrathoracic metastases, including brain metastases, or known malignant pleural or pericardial effusion
- •Prior radiation treatment less than 6 months from the planned start of reirradiation of any part of the intended treatment volume
- •Pregnant or breast-feeding patients. Men and women of reproductive potential may not participate in this study unless they have agreed to use an effective contraceptive method while in this study.
- •Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- •Known active Hepatitis B (e.g., HBsAg positive or HBV DNA detectable) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
研究组 & 干预措施
Single Arm
Experimental
Single Arm, Open Label
干预措施: Pembrolizumab (Drug)
结局指标
主要结局
Number of Subjects With Progression Free Survival
时间窗: 2 years
Progression Free Survival is defined as the time from initiation of definitive therapy to the first documented disease progression per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 based on radiologists' review or death due to any cause, whichever occurs first, or last patient follow-up that documented lack of disease progression. Patients who have not had disease progression or who have died, will be censored on the most recent clinical evaluation date that documented that they were progression-free.
次要结局
- Number of Participants Who Experienced a Grade 3+ Adverse Event(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without NephroureterectomyHigh Risk Superficial Upper Urinary Tract Transitional Cell CarcinomaEndoscopic Surgical ProcedureTransitional Epithelial CellsNCT03345134Shaheen Alanee20
已完成
1 期
Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal CancersColorectal CarcinomaColon DiseaseColorectal CancerColon CancerNCT03332498H. Lee Moffitt Cancer Center and Research Institute40
已完成
2 期
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Ductal AdenocarcinomaNCT03727880Lei Zheng28
进行中（未招募）
1 期
Standard of Care Chemotherapy Plus Pembrolizumab for Breast CancerTriple Negative Breast CancerNCT02734290Providence Health & Services29
已完成
2 期
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) CancerGastric CancerEsophageal CancerNCT02954536Memorial Sloan Kettering Cancer Center37